The US Food and Drug Administration (FDA) has granted fast track designation to SAR446268 for the treatment of non-congenital DM1 myotonic dystrophy type 1 (DM1). 

The announcement was made by pharmaceutical company Sanofi, who developed SAR446268 as a one-time gene therapy. Fast track designation will now facilitate the development and expedited review of SAR446268. 

SAR446268 employs a vectorised RNA interference (RNAi) approach to silence DMPK expression through a single administration. By reducing DMPK  transcripts, the gene therapy aims to eliminate the abnormal and toxic RNA foci responsible for splicing defects in muscle tissue, thereby restoring normal splicing and improving muscular function.  

The approach has the potential to address key symptoms of the disease, including progressive muscle weakness, difficulty relaxing muscles (myotonia), and effects on multiple body systems including heart, lungs, and endocrine functions. SAR446268 is the only investigational therapy in clinical development for this disease, and there are no currently approved therapies for DM1. 

SAR446268 is currently under investigation in a first-in-human, Phase I/II study to evaluate its safety, tolerability, and efficacy. The first patient is planned for enrolment in late 2025.  

Sanofi has already been granted orphan designations for SAR446268 in both the US (July 2024) and EU (October 2024). 

 

Bruno Quinney, Content Team, DDW